Organ Chimerization via Bone Marrow Cell Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current organ transplant methods face challenges with immune system rejection, particularly in cases where matching is not possible, leading to the need for immunosuppressive drugs that come with side effects and chronic rejection issues.
Innovation Solution
An in-vitro chimerization method involving washing and culturing organs with specific media solutions and bone marrow cells from the recipient to achieve genetic identity transfer, reducing immune response and potentially eliminating the need for immunosuppressants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunosuppressive drugs are used to overcome immune rejection, then organ transplant success rate is improved, but patient susceptibility to infections and malignancies increases
Solution Approach 1:
The patent extracts and removes donor DNA from the organ tissue through enzymatic digestion and washing procedures. This eliminates the foreign genetic material that triggers immune rejection, allowing the organ to be transplanted without immunosuppressive drugs, thereby resolving the contradiction between transplant success and infection risk
Solution Approach 2:
The patent creates a genetic copy of the recipient's DNA profile within the transplanted organ by introducing recipient leukocytes that carry the recipient's genetic information. This genetic copying makes the organ appear as self-tissue to the immune system, eliminating rejection without requiring immunosuppression
2Reliability
If matching is performed to ensure transplant compatibility, then immune rejection is reduced, but applicability is limited to organs that can be transplanted without affecting donor's life
Solution Approach 1:
The patent removes the limitation of donor-recipient matching by extracting donor DNA from the organ tissue. This allows any organ to be transplanted into any recipient regardless of HLA compatibility, as the immune system will not recognize foreign antigens when donor DNA is removed. This resolves the contradiction by making all organ types adaptable to this method
Solution Approach 2:
The patent changes the fundamental parameter of genetic identity in the transplanted organ from donor-derived to recipient-derived. By modifying the genetic composition parameter through leukocyte introduction, the method makes transplant compatibility independent of traditional matching parameters, expanding versatility to all organ types
3Reliability
If induction of transplant tolerance is performed by exposing patient to donor hematopoietic stem cells, then immune tolerance may be achieved, but outcomes are variable and limited to patients who previously received bone marrow transplant
Solution Approach 1:
Instead of exposing the patient to donor stem cells to induce tolerance (traditional approach), the patent inverts the approach by making the organ itself carry the recipient's genetic identity. This reversal eliminates the need for complex conditioning regimens and expands applicability to all patients regardless of prior bone marrow transplant history
Solution Approach 2:
The patent performs preliminary genetic modification of the organ before transplantation by introducing recipient leukocytes and allowing DNA transfer. This preliminary action establishes immune compatibility in advance, eliminating the need for post-transplant immunosuppression or complex tolerance induction protocols, thereby expanding versatility to broader patient populations
Data Source
AI summary
A method for organ and tissue chimerization using bone marrow cellular treatment, which avoids rejection of transplanted organs and diminishes or suspends the use of immunosuppressant drugs in patients subjected to transplant procedures. The method comprises washing the organ in an electrolyte solution. A further step of washing the organ in a wash solution. The organ is then placed in a culture solution and incubated with bone marrow cells.